Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 307-322

  Nagasawa, Daniel T ^a   Chow, Frances ^a   Yew, Andrew ^a   Kim, Won ^a   Cremer, Nicole ^a   Yang, Isaac ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCNU wafers; Bevacizumab; Glioblastoma multiforme; NovoTTF 100A; Temozolomide

Indexed keywords

3 METHYLADENINE; 7 METHYLGUANINE; BETA INTERFERON; BEVACIZUMAB; CARMUSTINE; CILENGITIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; DAPORINAD; DENDRITIC CELL VACCINE; DNA; DOUBLE STRANDED DNA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN A; VINCRISTINE; XL 765;

ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; BRAIN SURGERY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOSENSITIVITY; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DNA ALKYLATION; DNA CROSS LINKING; DNA METHYLATION; DNA MODIFICATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG UTILIZATION; ELECTRODE; ENZYME INHIBITION; EXCISION REPAIR; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); METRONOMIC DRUG ADMINISTRATION; MUCOCUTANEOUS CANDIDIASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; GLIOBLASTOMA; HUMANS; TREATMENT OUTCOME;

EID: 84858594427     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.007     Document Type: Review

References (153)

1. Wick W., Weller M., Weiler M., et al. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011, 13(6):566-579.
2. Hentschel S.J., Lang F.F. Current surgical management of glioblastoma. Cancer J 2003, 9(2):113-125.
3. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95(2):190-198.
4. Sanai N., Berger M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62(4):753-764. [discussion: 264-6].
5. Galanis E., Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer 2000, 82(8):1371-1380.
6. Sanai N., Berger M.S. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics 2009, 6(3):478-486.
7. Hentschel S.J., Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003, 10(2):109-114.
8. Litofsky N.S., Bauer A.M., Kasper R.S., et al. Image-guided resection of high-grade glioma: patient selection factors and outcome. Neurosurg Focus 2006, 20(4):E16.
9. Stummer W., Stocker S., Wagner S., et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998, 42(3):518-525. [discussion: 525-6].
10. Kelly P.J., Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994, 34(1):62-66. [discussion: 66-7].
11. Chinot O.L., Barrie M., Frauger E., et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100(10):2208-2214.
12. Quick A., Patel D., Hadziahmetovic M., et al. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 2010, 5(1):14-27.
13. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83(5):588-593.
14. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
15. van Genugten J.A., Leffers P., Baumert B.G., et al. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol 2010, 96(2):249-257.
16. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005, 23(10):2372-2377.
17. Combs S.E., Gutwein S., Schulz-Ertner D., et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 2005, 181(6):372-377.
18. Mirimanoff R.O., Gorlia T., Mason W., et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006, 24(16):2563-2569.
19. Chakravarti A., Erkkinen M.G., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006, 12(15):4738-4746.
20. Zhang M., Chakravarti A. Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol 2006, 16(1):29-37.
21. Kanzawa T., Bedwell J., Kondo Y., et al. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 2003, 99(6):1047-1052.
22. Clark A.S., Deans B., Stevens M.F., et al. Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J Med Chem 1995, 38(9):1493-1504.
23. Karran P., Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv 1996, 28:69-85.
24. Panetta J.C., Kirstein M.N., Gajjar A., et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 2003, 52(6):435-441.
25. Beale P., Judson I., Moore S., et al. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol 1999, 44(5):389-394.
26. Marzolini C., Decosterd L.A., Shen F., et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Cancer Chemother Pharmacol 1998, 42(6):433-440.
27. Horgan C.M., Tisdale M.J. Antitumour imidazotetrazines-VIII. Uptake and decomposition of a novel antitumour agent mitozolomide (CCRG 81010; M and B 39565; NSC 353451) in TLX5 mouse lymphoma in vitro. Biochem Pharmacol 1985, 34(2):217-221.
28. Schulman M.P., Buchanan J.M. Biosynthesis of the purines. II. Metabolism of 4-amino-5-imidazolecarboxamide in pigeon liver. J Biol Chem 1952, 196(2):513-526.
29. Baker S.D., Wirth M., Statkevich P., et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999, 5(2):309-317.
30. Reyderman L., Statkevich P., Thonoor C.M., et al. Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 2004, 34(5):487-500.
31. Meany H.J., Warren K.E., Fox E., et al. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 2009, 65(1):137-142.
32. Riccardi A., Mazzarella G., Cefalo G., et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Cancer Chemother Pharmacol 2003, 52(6):459-464.
33. Jen J.F., Cutler D.L., Pai S.M., et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000, 17(10):1284-1289.
34. Motomura K., Natsume A., Fujii M., et al. Clinical experience of intravenous temozolomide therapy for gliomas. J Clin Oncol 2011, 29(Suppl). [abstract: e12523].
35. Diez B.D., Statkevich P., Zhu Y., et al. Evaluation of the exposure equivalence of oral versus intravenous temozolomide. Cancer Chemother Pharmacol 2010, 65(4):727-734.
36. Patel M., McCully C., Godwin K., et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003, 61(3):203-207.
37. Rosso L., Brock C.S., Gallo J.M., et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009, 69(1):120-127.
38. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells: much more complex than expected. Mol Cancer 2011, 10:128.
39. Fisher T., Galanti G., Lavie G., et al. Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. Cancer J 2007, 13(5):335-344.
40. Lefranc F., Facchini V., Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007, 12(12):1395-1403.
41. Malkoun N., Chargari C., Forest F., et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 2012, 106(1):127-133.
42. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49(3):333-343.
43. Walker M.D., Green S.B., Byar D.P., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303(23):1323-1329.
44. van den Bent M.J., Taphoorn M.J., Brandes A.A., et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003, 21(13):2525-2528.
45. Osoba D., Brada M., Yung W.K., et al. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000, 36(14):1788-1795.
46. Perry J., Laperriere N., Zuraw L., et al. Adjuvant chemotherapy for adults with malignant glioma: a systematic review. Can J Neurol Sci 2007, 34(4):402-410.
47. Kocher M., Kunze S., Eich H.T., et al. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 2005, 181(3):157-163.
48. Lawrence Y.R., Wang M., Dicker A.P., et al. Early toxicity predicts long-term survival in high-grade glioma. Br J Cancer 2011, 104(9):1365-1371.
49. Lanzetta G., Campanella C., Rozzi A., et al. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 2003, 23(6D):5159-5164.
50. Kovacs J.A., Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000, 342(19):1416-1429.
51. Kizilarslanoglu M.C., Aksoy S., Yildirim N.O., et al. Temozolomide-related infections: review of the literature. J BUON 2011, 16(3):547-550.
52. Gilbert M.R., Gonzalez J., Hunter K., et al. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol 2010, 12(11):1167-1172.
53. Baruchel S., Diezi M., Hargrave D., et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006, 42(14):2335-2342.
54. Taphoorn M.J., Stupp R., Coens C., et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 2005, 6(12):937-944.
55. Brandsma D., Stalpers L., Taal W., et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet 2008, 9(5):453-461.
56. Chamberlain M.C., Glantz M.J., Chalmers L., et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82(1):81-83.
57. de Wit M.C., de Bruin H.G., Eijkenboom W., et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004, 63(3):535-537.
58. Rosenthal M.A., Ashley D.L., Cher L. Temozolomide-induced flare in high-grade gliomas: a new clinical entity. Intern Med J 2002, 32(7):346-348.
59. Taal W., Brandsma D., de Bruin H.G., et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113(2):405-410.
60. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26(13):2192-2197.
61. Easaw J.C., Mason W.P., Perry J., et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 2011, 18(3):e126-e136.
62. Mason W.P., Maestro R.D., Eisenstat D., et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 2007, 14(3):110-117.
63. Roldan G.B., Scott J.N., McIntyre J.B., et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009, 36(5):617-622.
64. Villano J., Seery T., Bressler L. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009, 64:647-655.
65. Hermisson M., Klumpp A., Wick W., et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006, 96(3):766-776.
66. Combs S.E., Schulz-Ertner D., Roth W., et al. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007, 68(3):873-882.
67. Balducci M., D'Agostino G.R., Manfrida S., et al. Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neurooncol 2010, 97(1):95-100.
68. Combs S.E., Wagner J., Bischof M., et al. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 2008, 71(4):999-1005.
69. Clarke J.L., Iwamoto F.M., Sul J., et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009, 27(23):3861-3867.
70. Simon R., Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006, 3(8):406-407.
71. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
72. Beier D., Rohrl S., Pillai D.R., et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008, 68(14):5706-5715.
73. Lam N., Chambers C.R. Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. J Oncol Pharm Pract 2011 Nov 7, [Epub ahead of print].
74. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10(6):1871-1874.
75. Kreth S., Thon N., Eigenbrod S., et al. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One 2011, 6(2):e17156.
76. Felsberg J., Rapp M., Loeser S., et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009, 15(21):6683-6693.
77. Costa B.M., Caeiro C., Guimaraes I., et al. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. Oncol Rep 2010, 23(6):1655-1662.
78. Sardi I., Cetica V., Massimino M., et al. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. Oncol Rep 2009, 22(4):773-779.
79. Weiler M., Hartmann C., Wiewrodt D., et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys 2010, 77(3):670-676.
80. Watanabe R., Nakasu Y., Tashiro H., et al. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. Brain Tumor Pathol 2011, 28(2):127-135.
81. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4(4):296-307.
82. Hotta T., Saito Y., Fujita H., et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21(2):135-140.
83. Belanich M., Pastor M., Randall T., et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996, 56(4):783-788.
84. Jaeckle K.A., Eyre H.J., Townsend J.J., et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16(10):3310-3315.
85. Friedman H.S., McLendon R.E., Kerby T., et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16(12):3851-3857.
86. Silber J.R., Blank A., Bobola M.S., et al. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999, 5(4):807-814.
87. Sridhar T., Gore A., Boiangiu I., et al. Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study. Clin Oncol 2009, 21(1):19-22.
88. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61(5):1957-1963.
89. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20(5):1375-1382.
90. Tsien C.I., Brown D., Normolle D., et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 2012, 18(1):273-279.
91. Darefsky A.S., King J.T., Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of surveillance, epidemiology, and end results registries. Cancer 2011, [Epub ahead of print]. 10.1002/cncr.26494.
92. Guckenberger M., Mayer M., Buttmann M., et al. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther Onkol 2011, 187(9):548-554.
93. Fadul C.E., Fisher J.L., Gui J., et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 2011, 13(4):393-400.
94. Wang H.Y., Wang R.F. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect 2005, 7(7-8):1056-1062.
95. Su Y.B., Sohn S., Krown S.E., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004, 22(4):610-616.
96. Liau L.M., Prins R.M., Kiertscher S.M., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005, 11(15):5515-5525.
97. Wheeler C.J., Das A., Liu G., et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004, 10(16):5316-5326.
98. Liu G., Akasaki Y., Khong H.T., et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 2005, 24(33):5226-5234.
99. Yip S., Miao J., Cahill D.P., et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009, 15(14):4622-4629.
100. Goellner E.M., Grimme B., Brown A.R., et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 2011, 71(6):2308-2317.
101. Tang J.B., Goellner E.M., Wang X.H., et al. Bioenergetic metabolites regulate base excision repair-dependent cell death in response to DNA damage. Mol Cancer Res 2010, 8(1):67-79.
102. Fishel M.L., He Y., Smith M.L., et al. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 2007, 13(1):260-267.
103. Watson M., Roulston A., Belec L., et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009, 29(21):5872-5888.
104. Russo A.L., Kwon H.C., Burgan W.E., et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009, 15(2):607-612.
105. Quinn J.A., Jiang S.X., Reardon D.A., et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009, 27(8):1262-1267.
106. Koch D., Hundsberger T., Boor S., et al. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol 2007, 82(1):85-89.
107. Motomura K., Natsume A., Kishida Y., et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 2010, [Epub ahead of print].
108. Bektas M., Johnson S.P., Poe W.E., et al. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol 2009, 64(5):1053-1058.
109. Bogdahn U., Hau P., Stockhammer G., et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011, 13(1):132-142.
110. Beal K., Abrey L.E., Gutin P.H. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011, 6:2.
111. Sampson J.H., Heimberger A.B., Archer G.E., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28(31):4722-4729.
112. Prasad G., Sottero T., Yang X., et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011, 13(4):384-392.
113. McLendon R., Friedman A., Bigner D., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068.
114. Cheng C.K., Fan Q.W., Weiss W.A. PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathol 2009, 19(1):112-120.
115. Maira S.M., Stauffer F., Brueggen J., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008, 7(7):1851-1863.
116. Opel D., Westhoff M.A., Bender A., et al. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008, 68(15):6271-6280.
117. Stupp R., Hegi M.E., Neyns B., et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28(16):2712-2718.
118. Cohen K.J., Pollack I.F., Zhou T., et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011, 13(3):317-323.
119. Pollack I.F., Hamilton R.L., James C.D., et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006, 105(Suppl 5):418-424.
120. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812.
121. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345(8956):1008-1012.
122. Bota D.A., Desjardins A., Quinn J.A., et al. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag 2007, 3(5):707-715.
123. Valtonen S., Timonen U., Toivanen P., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41(1):44-48. [discussion: 48-9].
124. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5(2):79-88.
125. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
126. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66(8):1258-1260.
127. Vredenburgh J.J., Desjardins A., Reardon D.A., et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011, 17(12):4119-4124.
128. Mendelsohn J., Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19(56):6550-6565.
129. Wong E.T., Gautam S., Malchow C., et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011, 9(4):403-407.
130. de Groot J.F., Yung W.K. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008, 14(5):279-285.
131. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787.
132. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740.
133. Salmaggi A., Gaviani P., Botturi A., et al. Bevacizumab at recurrence in high-grade glioma. Neurol Sci 2011, 2(Suppl 2):S251-S253.
134. Addeo R., Caraglia M., De Santi M.S., et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol 2011, 102(3):417-424.
135. Scoccianti S., Detti B., Sardaro A., et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 2008, 19(6):613-620.
136. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745.
137. Hofer S., Elandt K., Greil R., et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011, 50(5):630-635.
138. Reardon D.A., Desjardins A., Peters K.B., et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 2011, [Epub ahead of print].
139. Vredenburgh J.J., Desjardins A., Herndon J.E.I.I., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729.
140. Reardon D.A., Desjardins A., Vredenburgh J.J., et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009, 101(12):1986-1994.
141. Hasselbalch B., Lassen U., Hansen S., et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010, 12(5):508-516.
142. Pu J.K., Chan R.T., Ng G.K., et al. Using bevacizumab in the fight against malignant glioma: first results in Asian patients. Hong Kong Med J 2011, 17(4):274-279.
143. Lamborn K.R., Chang S.M., Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004, 6(3):227-235.
144. Ballman K.V., Buckner J.C., Brown P.D., et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007, 9(1):29-38.
145. Franceschi E., Brandes A.A. Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?. Expert Rev Anticancer Ther 2011, 11(5):657-660.
146. Thompson E.M., Frenkel E.P., Neuwelt E.A. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011, 76(1):87-93.
147. Kirson E.D., Dbaly V., Tovarys F., et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007, 104(24):10152-10157.
148. Stupp R., Kanner A., Engelhard H., et al. A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. J Clin Oncol 2010, 28(Suppl 18). [abstract: LBA2007].
149. Bronzino J. The biomedical engineering handbook 1995, CRC, IEEE Press, Boca Raton (FL), p. 1-1656.
150. Burnette R.R., Ongpipattanakul B. Characterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J Pharm Sci 1988, 77(2):132-137.
151. Cho M.R., Thatte H.S., Silvia M.T., et al. Transmembrane calcium influx induced by ac electric fields. FASEB J 1999, 13(6):677-683.
152. Orrenius S., McCabe M.J., Nicotera P. Ca(2+)-dependent mechanisms of cytotoxicity and programmed cell death. Toxicol Lett 1992, 64-65(Spec No):357-364.
153. Bock H.C., Puchner M.J., Lohmann F., et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010, 33(4):441-449.